Funding profile · Diagnostics software

Scanbase

One Form D exists for this company, and an investment vehicle filed it, not Scanbase. That vehicle sold $321,426 to 110 investors in April 2023. Nothing has been filed since.

$321,426Sold in full by the only Form D on record, filed May 2023
110Investors in that vehicle, about $2,922 each
$500KSeed total reported by aggregators, equal to the YC standard deal
0Form D filings by Scanbase, Inc. itself

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Winter 2023 Y Combinator batch $500,000 standard deal Y Combinator YC terms
Apr 17, 2023 SPV: Scanbase Leonis a Series of CGF2021 LLC $321,426 of $321,426 110 investors; administered by Sydecar LLC Form D
Apr 2023, reported Seed $500,000 Innovation Endeavors, Tucker Seed Fund LLC, Y Combinator, David Lieb, Sasha Medvedovsky Aggregator only
2023 Investors named on the company site Not disclosed Y Combinator, Liquid 2 Ventures, Rebel Fund, TRAC Company-stated
2023 Tracxn records two seed rounds $500K total Y Combinator only Differs from the list above
To Sep 2026 Any filing by Scanbase, Inc. None None Not found

What the filings show

Scanbase Leonis a Series of CGF2021 LLC · Form D · filed May 2, 2023

First sale
Apr 17, 2023
Type
Pooled investment fund, venture capital fund, Delaware series LLC formed 2023
Offered
$321,426
Sold
$321,426 · $0 remaining
Investors
110 · average about $2,922 · no non-accredited investors
Fees
Sales commissions $0 · finders fees $0 · $6,181 of proceeds for organizational and operating expenses
Exemptions
Rule 506(b); Investment Company Act 3(c)(1)
Related persons
Sydecar LLC (administrator of the issuer); Taylor Hughes (officer of the administrator), who signed as General Manager of the Administrator
Filing
SEC EDGAR, CIK 0001975962

Reading the filings

  1. The only filing is not the company’s.Scanbase, Inc. has no Form D of its own. The single notice on record was filed by a special purpose vehicle formed to buy into it. Companies that raise on SAFEs under Section 4(a)(2) file no Form D at all, so the absence does not mean no money moved. It does mean the company has never put its own offering amounts on the record.
  2. The checks are angel size, and there are a lot of them.$321,426 divided by 110 investors is about $2,922 each. That is a syndicate, not a fund. The vehicle sold out exactly: offered and sold are the same number, which is how a syndicate that allocates a fixed slot reports.
  3. The name points at the syndicate lead.The series is called Scanbase Leonis. Leonis.vc is the syndicate run by Gabriel Jarrosson, described by its SPV provider as one of the largest French angel syndicates, with over 750 investors, and Sydecar notes that “His syndicate, Leonis.vc, invests primarily in YC companies.” Sydecar LLC is named in the filing as administrator. The filing does not name the lead, so the connection rests on the series name and the administrator.
  4. The reported $500K is the accelerator deal.Aggregators list a $500K seed in April 2023. Y Combinator publishes the same number as its standard terms: “we invest $500,000. $125,000 of our investment converts into a fixed 7%, and the other $375,000 is invested on an uncapped MFN SAFE.” A reported total that matches the standard deal to the dollar is more likely the batch investment than a priced round.
  5. The investor lists do not agree.Startup Intros names Innovation Endeavors, Tucker Seed Fund LLC, Y Combinator, David Lieb and Sasha Medvedovsky. The company’s own about page names Y Combinator, Liquid 2 Ventures, Rebel Fund and TRAC. Tracxn names only Y Combinator, dates the founding to 2004 and describes the business as care planning software, which is wrong on both counts. None of the three lists can be checked against a filing.
  6. The filing was on time and the fees were small.First sale April 17, filed May 2, which is the 15 day deadline used to the day. $6,181 of organizational and operating expense is about 1.9% of the raise, and no commissions or finders fees were paid.

Commercial signals

Signal Detail Source type
Regulatory No FDA 510(k), PMA, EUA, establishment registration or device listing found under Scanbase. The software is sold to test makers, who carry their own submissions. Public record
Clinical evidence No registered trials, no PubMed publications, no NIH or NSF awards. Not found
Product scope More than 40 at-home lateral flow and colorimetric tests, plus all ADx and Whatman style dried blood spot cards, as of August 2023. Company-stated
Customers QuidelOrtho and Aster named in a July 2023 trade article. Neither confirmed elsewhere; the company names no customer. Unconfirmed
Pricing A vendor listing records subscription and usage pricing: “$50,000/mo (Model A); $0.0900/kit (Model B)”. Not published by the company. Third party listing
Revenue GetLatka lists $3M for 2024, labeled an estimate, and lists funding as $0 on the same page. Third party estimate
Headcount Y Combinator lists 10, Tracxn lists 9 as of Aug 2026, GetLatka lists 5. Sources disagree
Positioning The 2024 site sold a 4 to 6 week algorithm integration. The 2026 site sells consulting, implementation and support services. Company-stated

What to watch

  • A Form D from Scanbase, Inc. It has never filed one. A priced round would normally produce it within 15 days of first sale.
  • An FDA submission from a customer that names Scanbase as the reader, which would put accuracy data on the public record for the first time.
  • A named, confirmed customer, or a published revenue figure from the company rather than an estimate.
  • Whether a second syndicate vehicle appears, which would signal a follow on round raised the same way.

The Scanbase story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Dr. Treat: Shared investor: Liquid 2. A membership veterinary practice built around two clinics in the San Francisco Bay Area, pitched by its founders as “One Medical for pets” and backed by a seed round
  • Scanwell Health: Shared investor: Liquid 2. A Los Angeles company that turned a phone camera into a urinalysis reader and sold the first over-the-counter urine testing app in the United States
  • Instalab: Shared investor: Liquid 2. A New York concierge service that lets people order their own blood work, imaging and screenings, with a network of physicians authorizing the orders behind the scenes
  • Mecha Health: Shared investor: Rebel Fund. Four University College London researchers built a chest x-ray model that writes the whole report, published benchmarks saying it matches or beats radiologists, and

Sources

  1. Public recordForm D, Scanbase Leonis a Series of CGF2021 LLC, CIK 0001975962SEC · May 2, 2023
  2. Public recordSEC EDGAR search for Form D filings by or naming ScanbaseSEC · accessed Sep 24, 2026
  3. Public recordFDA 510(k), PMA, registration and listing searches; trial registry, NIH, NSF and PubMed searchesAccessed Sep 24, 2026
  4. IndependentThe Y Combinator Standard DealY Combinator · accessed Sep 24, 2026
  5. IndependentHow Sydecar Helped Leonis.VC Scale Their Syndicate to Over 750 MembersSydecar, Gavin Freeman · Apr 8, 2025
  6. IndependentScanbase: Funding, Team and InvestorsStartup Intros · accessed Sep 24, 2026
  7. IndependentScanbase company profileTracxn · accessed Sep 24, 2026
  8. IndependentScanbase Revenue 2024: $3M Est. ARRGetLatka · accessed Sep 24, 2026
  9. IndependentScanbase, Inc. company profile with pricing modelsSOTA2 · accessed Sep 24, 2026
  10. IndependentScanbase and the Future of Diagnostic Test AnalysisHiretop, Daryna Falko · Jul 6, 2023
  11. CompanyScanbase Revolutionizes At-Home Healthcare with AI-Powered Diagnostic SolutionsPR Newswire · Aug 16, 2023
  12. CompanyScanbase website about page investor list, home and solutions pagesAccessed Sep 24, 2026
  13. CompanyScanbase home page captureInternet Archive · Jan 5, 2024
  14. CompanyScanbase company page, Winter 2023 batchY Combinator · accessed Sep 24, 2026

Compiled from SEC, FDA, NIH, NSF and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Healthcare Venture Capital Fund holds no position in Scanbase. This page is not an offer to sell or a recommendation to buy any security.